Company Description
Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China.
The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.
It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.
In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application.
Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth.
Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.
| Country | China |
| IPO Date | Jan 12, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 298 |
| CEO | Zhanchang Xin |
Contact Details
Address: No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District Chengdu, F4 610200 China | |
| Phone | 86-0937-2689523 |
| Website | qlsyy.net |
Stock Details
| Ticker Symbol | QLI |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001779578 |
| CUSIP Number | G7307E107 |
| ISIN Number | KYG7307E1070 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Zhanchang Xin | Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer and Chief Scientific Officer |
| Haiping Shi | Chief Financial Officer |
| Dingqian Liu | Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2024 | EFFECT | Notice of Effectiveness |
| May 8, 2024 | F-3/A | Filing |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 10, 2024 | F-3 | Filing |
| Mar 11, 2024 | 6-K | Report of foreign issuer |
| Feb 15, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Feb 1, 2024 | NT 20-F | Notification of inability to timely file Form 20-F |
| Dec 20, 2023 | 6-K | Report of foreign issuer |
| Dec 7, 2023 | 6-K | Report of foreign issuer |